Day: April 17, 2026

Carbios significantly reduced its operating expenses during 2025, resulting in a €7 million reduction in operating loss Carbios has a solid cash position of €59 million as of December 31, 2025, on a Group basis including subsidiaries1, enabling it to cover its operating expenses beyond the next 12 months. Projected cash consumption for 2026, excluding the Longlaville project, is estimated at €20 million The 4 strategic priorities for 2026 are:Resume the Longlaville industrial project, subject to the completion of its financing, with closing expected by Q3 20262 Deploy Carbios’ PET biorecycling technology in Asia through the construction of a first facility operated under a license agreement with Wankai Accelerate the commercial development to secure new license agreements across Europe, North America and South America Maintain a strict...

Quarterly direct result per share (DRPS) € 0.45, +2% compared with prior year period Occupancy shopping centers 97.5%, up 1.0 percentage point (pp) compared with Q1 2025 Quarterly Full Service Center footfall +2.0% compared with prior year period € 12m in strategic acquisitions closed, funded through issuance of new shares, resulting in a 0.2 pp improvement in loan-to-value Refinancing of € 250m revolving credit facility (RCF) completed, at improved terms, with a tenor of five years plus extension options up to seven years Despite ongoing geopolitical tensions, we remain confident in our 2026 DRPS forecast of € 1.85-1.95AttachmentWereldhave_Trading-update-Q1-2026

NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 1,740,000 additional...

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D. Bertrand to its Board of Directors as an independent director, effective immediately. Mr. Bertrand is a healthcare technology executive with more than a decade of experience driving AI-enabled innovation in diagnostics. He co-founded Digital Diagnostics Inc. and most recently served as its Chief Executive Officer, helping to transform the company from a research-stage organization into a global commercial platform for disease diagnosis. Previously, Mr. Bertrand...